Therefore, the aim of this study was to describe temporal trends and examine rural-urban differences in GEP testing among women diagnosed with early-stage, HR+, HER2−, and LN− breast cancer in Iowa and among women who received ODX, determining how the results are associated with chemotherapy use. The gene discussed is HR; the disease is breast cancer.